Israel-based pharmaceutical company Panaxia Pharmaceutical Industries Ltd. announced that it has started conducting clinical trials for fast-acting cannabis tablets. These tablets are designed to dissolve under the tongue.
Sublingual application is considered to be one of the quickest ways for a medication to be absorbed into a person’s bloodstream. Therefore, these sublingual cannabis tablets could provide a great alternative to vaping or smoking.
Dr. Silviu Brill, director of the Chronic and Acute Pain Center at the Tel-Aviv Sourasky Medical Center, said that when it comes to extended chronic pain, there is a significant advantage for treatment options that offer an immediate response and a longer-lasting effect.
According to Panaxia’s press release, if these sublingual tablets are approved, it could be great news for patients who are suffering from persistent or chronic pain.
Dr. Brill explained that tablets are a simple, familiar, and convenient treatment administration method for patients who are suffering from chronic pain. This will also enable doctors to better manage pain treatment using medical cannabis as it will help ensure consistent and precise dosages for patients.
Panaxia plans to launch the sublingual cannabis tablets in Israel this year. They will be distributed by pharmaceutical company Rafa.
Panaxia manufactures medicinal products like cannabis oil, suppositories, creams, pain relief patches, and vape cartridges that are intended to treat conditions like cancer, chronic pain, post-traumatic stress disorder, epilepsy, burns, and anorexia.